Latest News & Updates

Breaking News

  • 26 minutes ago

  • Vaibhavi M.

The United Laboratories International Holdings Limited (TUL) And Novo Nordisk Report Positive Phase 2 Data For UBT251 Triple Agonist In Obesity
Breaking News
European Medicines Agency Authorizes Oryzon’s Phase II IDEAL Trial Of Iadademstat In Essential Thrombocythemia

Vaibhavi M.

Other trending news you may like to read

The United Laboratories International Holdings Limited (TUL) And Novo Nordisk Report Positive Phase 2 Data For UBT251 Triple Agonist In Obesity

TUL and Novo Nordisk report 19.7% weight loss in Phase 2 trial of UBT251 triple agonist for obesity.

Vaibhavi M.

Pharma Now

European Medicines Agency Authorizes Oryzon’s Phase II IDEAL Trial Of Iadademstat In Essential Thrombocythemia

EMA authorizes Oryzon’s Phase II IDEAL trial of iadademstat in essential thrombocythemia.

Vaibhavi M.

Pharma Now

Kyverna Therapeutics Inc. Strengthens Board With The Addition Of Sravan K. Emany And Andrew Miller, Ph.D., Marking A Key Transition In Its Autoimmune CAR T Growth Strategy

Kyverna Therapeutics appoints Sravan Emany and Andrew Miller to strengthen its autoimmune CAR T strategy.

Simantini Singh Deo

Pharma Now

Cosmos Health Inc. Appoints Dimitrios Iliopoulos To Its Advisory Board To Advance AI-Powered Drug Discovery And Clinical-Stage Biotechnology Strategy

Cosmos Health Inc. appoints AI drug-discovery expert Dimitrios Iliopoulos to strengthen biotech strategy.

Simantini Singh Deo

Pharma Now